Leonardo Forero

3.6k total citations
7 papers, 113 citations indexed

About

Leonardo Forero is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Leonardo Forero has authored 7 papers receiving a total of 113 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in Leonardo Forero's work include Neutropenia and Cancer Infections (4 papers), Cancer therapeutics and mechanisms (3 papers) and Cancer Treatment and Pharmacology (2 papers). Leonardo Forero is often cited by papers focused on Neutropenia and Cancer Infections (4 papers), Cancer therapeutics and mechanisms (3 papers) and Cancer Treatment and Pharmacology (2 papers). Leonardo Forero collaborates with scholars based in United States, Canada and Germany. Leonardo Forero's co-authors include Chris H. Takimoto, Anthony W. Tolcher, Johann S. de Bono, Eric K. Rowinsky, Amita Patnaik, Lisa A. Hammond, Muralidhar Beeram, Bahram Forouzesh, Leslie Wood and Jane E. Latz and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Leonardo Forero

6 papers receiving 113 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leonardo Forero United States	4	66	47	39	21	15	7	113
Matteo Duca Italy	5	81 1.2×	40 0.9×	57 1.5×	17 0.8×	36 2.4×	18	143
Sue Cheeseman United Kingdom	7	94 1.4×	42 0.9×	86 2.2×	12 0.6×	5 0.3×	23	178
Arnaldo Marín Chile	5	61 0.9×	52 1.1×	48 1.2×	33 1.6×	10 0.7×	12	136
David Sommerhalder United States	7	66 1.0×	89 1.9×	47 1.2×	14 0.7×	29 1.9×	43	162
Francesca Pettinella United States	4	75 1.1×	29 0.6×	19 0.5×	51 2.4×	11 0.7×	8	122
Wendy Crist United States	8	79 1.2×	83 1.8×	24 0.6×	11 0.5×	14 0.9×	11	142
Wendong Lei China	4	84 1.3×	39 0.8×	47 1.2×	9 0.4×	17 1.1×	10	126
Julia Dudnik Israel	9	86 1.3×	32 0.7×	89 2.3×	8 0.4×	17 1.1×	23	143
Alejandro Falcón Spain	6	89 1.3×	54 1.1×	44 1.1×	14 0.7×	3 0.2×	29	135
Shen Lao China	6	89 1.3×	50 1.1×	39 1.0×	6 0.3×	52 3.5×	11	172

Countries citing papers authored by Leonardo Forero

Since Specialization

Citations

This map shows the geographic impact of Leonardo Forero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonardo Forero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonardo Forero more than expected).

Fields of papers citing papers by Leonardo Forero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonardo Forero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonardo Forero. The network helps show where Leonardo Forero may publish in the future.

Co-authorship network of co-authors of Leonardo Forero

This figure shows the co-authorship network connecting the top 25 collaborators of Leonardo Forero. A scholar is included among the top collaborators of Leonardo Forero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonardo Forero. Leonardo Forero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Nabavizadeh, Nima, Christina G. McDonnell, Marc Matrana, et al.. (2025). LBA64 Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: Initial results from the registrational PATHFINDER II study. Annals of Oncology. 36. S1605–S1605.

2.

Rodón, Jordi, Mitchell Garrison, Lisa A. Hammond, et al.. (2008). Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 62(5). 911–919. 25 indexed citations

3.

Takimoto, Chris H., Jane E. Latz, Leonardo Forero, et al.. (2007). Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer. Clinical Cancer Research. 13(9). 2675–2683. 44 indexed citations

4.

Mita, Monica, Eric K. Rowinsky, Leonardo Forero, et al.. (2006). A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology. 59(2). 165–174. 32 indexed citations

5.

Ricart, Alejandro D., Lisa A. Hammond, John G. Kuhn, et al.. (2005). Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research. 11(24). 8728–8736. 9 indexed citations

6.

Calvo, Emiliano, Eric K. Rowinsky, A. W. Tolcher, et al.. (2004). A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 2099–2099. 2 indexed citations

7.

Calvo, Emiliano, Eric K. Rowinsky, A. W. Tolcher, et al.. (2004). A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 2099–2099. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact